Month: June 2026

Introduction and Objective: Evidence of sodium-glucose cotransporter-2 inhibitors (SGLT2i) in type 1 diabetes (T1D) is limited to short-term trials with surrogate endpoints. Using real-world data, we aimed to assess long-term clinical outcomes of SGLT2i in T1D.Methods: Using electronic health record data from Optum Labs Data Warehouse, we conducted monthly sequential target trial emulation (SGLT2i initiation […]

Introduction and Objective: Diabetic foot ulcers complicated by lower limb ischemia are common complications in the person with diabetes, leading to non-traumatic amputations. Currently, there are no specific drugs, and treatment is limited to surgical intervention. This study explores the therapeutic effects and mechanisms of multi-cell fusion-based 3D-printed bioengineered skin, incorporating engineered exosomes, for treating […]

Introduction and Objective: Detecting dysglycemia at early stages of T1D can prevent DKA and improve long-term outcomes. OGTT, currently recommended for monitoring progression, can be challenging in clinical care. HbA1c is not sufficiently sensitive, particularly in young children. We aimed to identify CGM metrics predicting progression to stage 3 T1D.Methods: 171 participants prospectively followed in […]

Introduction and Objective: Maternal obesity is increasingly recognized as a determinant of long-term metabolic risk in offspring, yet the cellular mechanisms by which maternal nutritional status primes adipose tissue for coordinated remodeling across generations remain poorly defined. Traditional research has focused on metabolic dysfunction, failing to explain why certain maternal-offspring dietary combinations produce distinct phenotypic […]

Introduction and Objective: Given the urgent clinical need to restore long term blood glucose control, this study has established efficacy of BI-1622, a Her2 inhibitor initially developed for therapy of Her2-associated cancer, for diabetes intervention in preclinical models and human islets.Methods: BI-1622 (10 mg/kg) or vehicle was i.p. injected for 4 weeks into db/db, multiple […]

Introduction and Objective: Diabetic foot ulcers (DFUs) are chronic, slow-healing wounds characterized by unresolved inflammation affecting a significant proportion of patients with diabetes. Dysregulated NLRP3 inflammasome activation in diabetic wounds contributes to chronic inflammation, impeding tissue repair and promoting ulcer chronicity. NLRP3 expression is significantly upregulated in patients with DFUs compared to healthy controls.Methods: THP-1 […]

Introduction and Objective: The increasing prevalence of type 2 diabetes (T2D) requires a novel, disease-modifying treatment to target the root cause of diabetic progression: the loss of pancreatic β cell function. Recent clinical data has shown that patients diagnosed with T2D have a >80% loss in functional pancreatic β cell mass, which is not reversed […]

Introduction and Objective: Women with T1D have increased risk of CVD. Whether CVD risk factors worsen during the menopausal transition is unclear.Methods: We conducted a secondary analysis of women who had undergone natural menopause (n=243) in the Epidemiology of Diabetes Interventions and Complications Study (EDIC), a prospective observational study of persons with T1D originally enrolled […]

Introduction and Objective: Type 1 diabetes (T1D) is characterized by T and B cell responses to pancreatic β islet cell proteins, insulitis, and β islet cell loss. Treatment of NOD mice, at 6 or 10 weeks of age, with poly(lactic-co-glycolic acid) (PLGA) nanoparticles (CNPs) containing recombinant insulin, GAD65, and chromogranin A proteins (CNP-T1D) inhibited antigen […]